With the European Union formally reversing its marketing authorization for the rare-disease med Tavneos last week, regulators in the bloc are laying out their concerns about the data backing the complement inhibitor in greater detail.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
